Table 1.

Tables 1A and 1B

1A: Analysis of Sepax Clinical Separations
	TNC	TRC	%TNC Rec	%TRC Depl	Total ISHAGE CD34+	% Lymph	% Mono	% Gran
Mean	5.51×108	1.85×109	23.6	100.0	3.33×106	42.4	9.2	38.0
Std Dev	3.21×108	2.65×109	5.9	0.0	1.65×106	17.2	9.3	15.6
Median	4.83×108	1.34×109	23.7	100.0	3.06×106	42.5	8.0	39.0
Range	0.094*–18.3×108	0.032*–4.0×1010	0.7*–39.7	99.9*–100.0	0.021*–10×106	0†–95.0	0†–112.7	0†–78.0
1B: Analysis of Final Product Doses - 1/3 patients received placebo in place of cells‡
	TIME/Late-TIME Products				FOCUS Products
	TNC Dose		Total RBC Dose		TNC Dose		Total RBC Dose
N =	177		177		92		92
Mean	1.47×108		1.92×109		9.94×107		3.72×108
Std Dev	1.55×107		1.75×1010		4.55×106		2.21×108
Median	1.50×108		4.58×108		1.00×108		3.09×108
Range	0.036 – 1.50×108		0.017 – 23.3×1010		0.61 – 1.01×108		0.13 – 1.58×109

^*Lower value represents cells recovered after a Sepax device failure. Cells were recovered manually from the Sepax.

^† Lower values represent out of range results obtained from automated counters

^‡Products were prepared for all recipients. Randomization to active or placebo arm occurred following product preparation. Results shown are for all products prepared.